JP2012507270A5 - - Google Patents

Download PDF

Info

Publication number
JP2012507270A5
JP2012507270A5 JP2011533718A JP2011533718A JP2012507270A5 JP 2012507270 A5 JP2012507270 A5 JP 2012507270A5 JP 2011533718 A JP2011533718 A JP 2011533718A JP 2011533718 A JP2011533718 A JP 2011533718A JP 2012507270 A5 JP2012507270 A5 JP 2012507270A5
Authority
JP
Japan
Prior art keywords
rad35
bioreactor
cells
perfusion system
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011533718A
Other languages
English (en)
Japanese (ja)
Other versions
JP5770633B2 (ja
JP2012507270A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2009/064265 external-priority patent/WO2010060719A1/en
Publication of JP2012507270A publication Critical patent/JP2012507270A/ja
Publication of JP2012507270A5 publication Critical patent/JP2012507270A5/ja
Application granted granted Critical
Publication of JP5770633B2 publication Critical patent/JP5770633B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011533718A 2008-11-03 2009-10-29 アデノウイルスベクターの産生方法 Expired - Fee Related JP5770633B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US19812208P 2008-11-03 2008-11-03
EP08168181 2008-11-03
EP08168181.9 2008-11-03
US61/198,122 2008-11-03
PCT/EP2009/064265 WO2010060719A1 (en) 2008-11-03 2009-10-29 Method for the production of adenoviral vectors

Publications (3)

Publication Number Publication Date
JP2012507270A JP2012507270A (ja) 2012-03-29
JP2012507270A5 true JP2012507270A5 (https=) 2012-12-13
JP5770633B2 JP5770633B2 (ja) 2015-08-26

Family

ID=40344776

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011533718A Expired - Fee Related JP5770633B2 (ja) 2008-11-03 2009-10-29 アデノウイルスベクターの産生方法

Country Status (15)

Country Link
US (1) US10041049B2 (https=)
EP (1) EP2350268B1 (https=)
JP (1) JP5770633B2 (https=)
KR (1) KR101504392B1 (https=)
CN (1) CN102203242B (https=)
AU (1) AU2009319254B2 (https=)
BR (1) BRPI0921651A2 (https=)
CA (1) CA2742474C (https=)
DK (1) DK2350268T3 (https=)
EA (1) EA019928B1 (https=)
ES (1) ES2532015T3 (https=)
MX (1) MX2011004292A (https=)
NZ (1) NZ593235A (https=)
PL (1) PL2350268T3 (https=)
WO (1) WO2010060719A1 (https=)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102203242B (zh) 2008-11-03 2013-06-12 克鲁塞尔荷兰公司 产生腺病毒载体的方法
CN102575233B (zh) 2009-10-15 2014-07-16 克鲁塞尔荷兰公司 从高细胞密度培养物纯化腺病毒的方法
EA028623B1 (ru) 2009-10-15 2017-12-29 Янссен Вэксинс Энд Превеншн Б.В. Способ очистки аденовирусных частиц
MX2012007936A (es) * 2010-02-15 2012-11-22 Crucell Holland Bv Metodo para la produccion de vectores adenovirales del serotipo 26 del adenovirus.
EP2618838A1 (en) 2010-09-20 2013-07-31 Crucell Holland B.V. Therapeutic vaccination against active tuberculosis
MX354752B (es) 2010-09-27 2018-03-20 Janssen Vaccines & Prevention Bv Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria.
US8845902B2 (en) 2011-02-10 2014-09-30 Crucell Holland B.V. Pneumatic alternating pressure membrane cell separation system
WO2013074501A1 (en) 2011-11-14 2013-05-23 Crucell Holland B.V. Heterologous prime-boost immunization using measles virus-based vaccines
JP5770952B2 (ja) 2012-03-12 2015-08-26 クルセル ホランド ベー ヴェー 改変末端を有する組換えアデノウイルスのバッチ
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
US9119813B2 (en) 2012-03-22 2015-09-01 Crucell Holland B.V. Vaccine against RSV
EA026504B1 (ru) 2012-03-22 2017-04-28 Круселл Холланд Б.В. Вакцина против rsv
JP6469081B2 (ja) 2013-04-25 2019-02-13 ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. 安定化された可溶性融合前rsvfポリペプチド
MY171210A (en) 2013-06-17 2019-10-02 Janssen Vaccines & Prevention Bv Stabilized soluble pre-fusion rsv f polypeptides
US10392603B2 (en) * 2013-08-30 2019-08-27 The Chemo-Sero-Therapeutic Research Institute Method of viral purification
WO2015148704A1 (en) 2014-03-25 2015-10-01 Terumo Bct, Inc. Passive replacement of media
HUE040440T2 (hu) 2014-11-04 2019-03-28 Janssen Vaccines & Prevention Bv Terápiás HPV16-oltóanyagok
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
CN107847581B (zh) 2015-07-07 2022-03-22 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽
ES2839880T3 (es) 2015-07-07 2021-07-06 Janssen Vaccines & Prevention Bv Vacuna contra el VRS
US9663766B2 (en) 2015-07-24 2017-05-30 Bio-Rad Laboratories, Inc. Methods for purifying adenovirus vectors
KR20180042295A (ko) 2015-08-20 2018-04-25 얀센 백신스 앤드 프리벤션 비.브이. 치료용 hpv18 백신
KR102500970B1 (ko) 2016-04-05 2023-02-17 얀센 백신스 앤드 프리벤션 비.브이. Rsv에 대한 백신
PH12022552125A1 (en) 2016-04-05 2023-04-12 Janssen Vaccines & Prevention Bv Stabilized soluble pre-fusion rsv f proteins
WO2017180724A1 (en) * 2016-04-12 2017-10-19 Artemis Biosystems, Inc. Perfusion filtration systems
EP3452087A1 (en) 2016-05-02 2019-03-13 Janssen Vaccines & Prevention B.V. Therapeutic hpv vaccine combinations
JP7034949B2 (ja) 2016-05-25 2022-03-14 テルモ ビーシーティー、インコーポレーテッド 細胞の増殖
IL264119B2 (en) 2016-05-30 2023-04-01 Janssen Vaccines Prevention B V f proteins of rsv are stabilized before fusion
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US10744196B2 (en) 2016-07-14 2020-08-18 Janssen Vaccines & Prevention B.V. HPV vaccines
CN117247899A (zh) 2017-03-31 2023-12-19 泰尔茂比司特公司 细胞扩增
US11229692B2 (en) 2017-05-17 2022-01-25 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against RSV infection
WO2019053109A1 (en) 2017-09-15 2019-03-21 Janssen Vaccines & Prevention B.V. METHOD FOR SAFE INDUCTION OF IMMUNITY AGAINST RSV
WO2019086450A1 (en) 2017-10-31 2019-05-09 Janssen Vaccines & Prevention B.V. Adenovirus and uses thereof
MA50502A (fr) 2017-10-31 2020-09-09 Janssen Vaccines & Prevention Bv Adénovirus et utilisations associées
BR112020008435A2 (pt) 2017-10-31 2020-11-17 Janssen Vaccines & Prevention B.V. vetores de adenovírus e seus usos
WO2019086466A1 (en) 2017-10-31 2019-05-09 Janssen Vaccines & Prevention B.V. Adenovirus and uses thereof
KR20250111232A (ko) * 2017-12-11 2025-07-22 암젠 인크 이중특이적 항체 생성물의 연속 제조 공정
CN110317832B (zh) 2018-03-28 2022-07-05 西比曼生物科技(香港)有限公司 Gmp级规模化制备重组慢病毒载体的纯化制剂的方法
CN110317791A (zh) 2018-03-29 2019-10-11 西比曼生物科技(香港)有限公司 Gmp级无血清悬浮细胞大规模生产慢病毒的方法
US12060583B2 (en) 2018-04-24 2024-08-13 Merck Sharp & Dohme Llc Scalable chromatography process for purification of human cytomegalovirus
JP2022513025A (ja) 2018-11-13 2022-02-07 ヤンセン ファッシンズ アンド プリベンション ベーフェー 安定化された融合前rsv fタンパク質
WO2021003188A1 (en) * 2019-07-01 2021-01-07 Ology Bioservices, Inc. Method for cultivation of adherent cells in a multiparallel bioreactor
TW202204380A (zh) 2020-01-31 2022-02-01 美商詹森藥物公司 用於預防及治療冠狀病毒感染之組合物及方法-sars-cov-2疫苗
GB202013940D0 (en) 2020-09-04 2020-10-21 Synpromics Ltd Regulatory nucleic acid sequences
AU2021358957A1 (en) 2020-10-07 2023-06-08 AskBio Inc. Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy. disorders including limb girdle 21
KR20230165275A (ko) 2021-04-01 2023-12-05 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 융합 전 piv3 f 단백질
WO2023020939A1 (en) 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023111725A1 (en) 2021-12-14 2023-06-22 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
EP4448802A1 (en) 2021-12-16 2024-10-23 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion hmpv fusion proteins
WO2024061753A1 (en) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Stabilized trimeric class i fusion proteins
WO2024061757A1 (en) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Pre-fusion human piv1 f proteins
CN120344553A (zh) 2022-10-06 2025-07-18 Msd国际商务股份有限公司 稳定的融合前piv3 f蛋白
WO2024190895A1 (ja) 2023-03-15 2024-09-19 東レ株式会社 フィルターユニット、精製装置及び精製液の製造方法

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04241381A (ja) 1991-01-16 1992-08-28 Brother Ind Ltd 電子学習機
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
JP3816518B2 (ja) 1994-06-10 2006-08-30 ジェンベク、インコーポレイティッド 相補的なアデノウイルスベクター系と細胞系
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5770442A (en) 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
SI0833934T2 (sl) 1995-06-15 2013-04-30 Crucell Holland B.V. Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji
AU722196B2 (en) 1995-08-30 2000-07-27 Genzyme Corporation Chromatographic purification of adenovirus and AAV
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US5891690A (en) 1996-04-26 1999-04-06 Massie; Bernard Adenovirus E1-complementing cell lines
EP0944717A1 (fr) 1996-07-01 1999-09-29 Aventis Pharma S.A. Procede de production d'adenovirus recombinants
FR2751343B1 (fr) 1996-07-16 1998-12-18 Transgene Sa Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
ES2278399T3 (es) 1996-11-20 2007-08-01 Introgen Therapeutics, Inc. Metodo mejorado para la produccion y purificacion de vectores adenovirales.
US7732129B1 (en) * 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US6261823B1 (en) 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
CA2283253A1 (en) 1997-03-04 1998-09-11 Baxter International Inc. Adenovirus e1-complementing cell lines
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US6210683B1 (en) 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
KR100912362B1 (ko) 1998-02-17 2009-08-19 쉐링 코포레이션 바이러스 제제의 정제방법
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
JP2002512361A (ja) 1998-04-22 2002-04-23 ジェンベク、インコーポレイティッド アデノウイルスの効率的精製
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
US20040043489A1 (en) 1998-07-08 2004-03-04 Menzo Havenga Gene delivery vectors provided with a tissue tropism for dendritic cells and methods of use
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
DE69940354D1 (de) 1998-11-16 2009-03-12 Introgen Therapeutics Inc Adenovirus-formulierungen zur gentherapie
CA2356373A1 (fr) 1998-12-31 2000-07-13 Aventis Pharma S.A. Methode de separation de particules virales
EP1155120B1 (fr) 1999-02-22 2006-07-05 Transgene S.A. Procede d'obtention d'une preparation virale purifiee
ATE519855T1 (de) 1999-05-17 2011-08-15 Crucell Holland Bv Rekombinantes adenovirus des serotyps ad11
US20050232900A1 (en) 1999-05-18 2005-10-20 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
DE19955558C2 (de) 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
US6544424B1 (en) 1999-12-03 2003-04-08 Refined Technology Company Fluid filtration system
EP2420247A1 (en) 2000-03-07 2012-02-22 Merck Sharp & Dohme Corp. Adenovirus formulations
DE60138403D1 (de) 2000-09-26 2009-05-28 Crucell Holland Bv Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten
US20020064860A1 (en) 2000-11-29 2002-05-30 Schering Corporation Method for purifying adenoviruses
EP1453536A4 (en) 2001-12-12 2009-08-26 Mayne Pharma Int Pty Ltd COMPOSITION FOR PRESERVING VIRUSES
WO2003062400A2 (en) 2002-01-24 2003-07-31 The Scripps Research Institute Fiber shaft modifications for efficient targeting
US20030180936A1 (en) 2002-03-15 2003-09-25 Memarzadeh Bahram Eric Method for the purification, production and formulation of oncolytic adenoviruses
KR101021387B1 (ko) 2002-04-25 2011-03-14 크루셀 홀란드 비.브이. 아데노바이러스 벡터를 생산하기 위한 수단 및 방법
DK1497440T3 (da) 2002-04-25 2008-12-01 Crucell Holland Bv Stabile adenovirale vektorer og fremgangsmåder til propagering deraf
DE60335672D1 (de) 2002-05-14 2011-02-17 Merck Sharp & Dohme Verfahren zur reinigung von adenovirus
EP1553983A2 (en) 2002-10-23 2005-07-20 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
US20080153083A1 (en) 2003-10-23 2008-06-26 Crucell Holland B.V. Settings for recombinant adenoviral-based vaccines
WO2004055187A1 (en) 2002-12-17 2004-07-01 Crucell Holland B.V. Recombinant viral-based malaria vaccines
CA2519680A1 (en) 2003-03-28 2004-11-18 The Scripps Research Institute Adenovirus particles with enhanced infectivity of dendritic cells and particles with decreased infectivity of hepatocytes
HRP20130616T1 (en) 2003-10-02 2013-08-31 Crucell Holland B.V. Packaging cells for recombinant adenovirus
NZ548495A (en) * 2004-02-23 2009-05-31 Crucell Holland Bv Virus purification methods
CA2557046A1 (en) * 2004-03-05 2005-10-13 John Crowley Process for cell culturing by continuous perfusion and alternating tangential flow
MXPA06014099A (es) 2004-06-04 2007-05-09 Xcellerex Inc Sistemas biorreactores desechables y metodos.
BRPI0516048A (pt) 2004-10-13 2008-08-19 Crucell Holland B V E Beth Isr batelada de um adenovìrus recombinante defectivo em replicação baseado em um sorotipo do subgrupo c
ES2371175T3 (es) 2004-10-14 2011-12-28 Crucell Holland B.V. Vacunas de sensibilización/refuerzo de malaria.
SG159555A1 (en) 2004-11-16 2010-03-30 Crucell Holland Bv Multivalent vaccines comprising recombinant viral vectors
JP2008538894A (ja) 2005-02-11 2008-11-13 メルク エンド カムパニー インコーポレーテッド アデノウイルス血清型26ベクター、核酸およびそれにより製造されたウイルス
DK1869171T4 (en) 2005-04-11 2016-01-18 Crucell Holland Bv Virus cleaning using ultrafiltration
CA2609276A1 (en) 2005-05-23 2006-11-30 De-Chu C. Tang Rapid production of adenovirus-free recombinant adenovirus vectors
US20100115874A1 (en) 2005-07-22 2010-05-13 Pergo (Europe) Ab Flooring system including a dry glue
JP2009512421A (ja) 2005-08-15 2009-03-26 ヴァクシン インコーポレイテッド 非複製性ベクターワクチン投与による鳥類への免疫方法
US20100143302A1 (en) 2006-03-16 2010-06-10 Crucell Holland B.V. Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof
US20090110695A1 (en) 2006-03-27 2009-04-30 Menzo Jans Emko Havenga Compositions Comprising a Recombinant Adenovirus and an Adjuvant
ES2437082T3 (es) 2006-07-18 2014-01-08 Glaxosmithkline Biologicals S.A. Vacunas contra la malaria
HRP20161606T1 (hr) 2007-03-02 2017-01-13 Glaxosmithkline Biologicals Sa Novi postupak i pripravci
US9109193B2 (en) 2007-07-30 2015-08-18 Ge Healthcare Bio-Sciences Corp. Continuous perfusion bioreactor system
JP5795164B2 (ja) 2007-11-14 2015-10-14 チャン、チュン−チエ リチウムイオン電池での適用のための空気感受性電極材料を製造するための方法および装置
WO2009117134A2 (en) 2008-03-21 2009-09-24 National Institutes Of Health Aerosolized genetic vaccines and methods of use
CN102203242B (zh) 2008-11-03 2013-06-12 克鲁塞尔荷兰公司 产生腺病毒载体的方法
AP3140A (en) 2009-07-16 2015-02-28 Crucell Holland Bv Production of polio virus at high titers for vaccine production
CN102575233B (zh) 2009-10-15 2014-07-16 克鲁塞尔荷兰公司 从高细胞密度培养物纯化腺病毒的方法
MX2012007936A (es) 2010-02-15 2012-11-22 Crucell Holland Bv Metodo para la produccion de vectores adenovirales del serotipo 26 del adenovirus.
US20120315696A1 (en) 2010-02-15 2012-12-13 Alfred Luitjens METHOD FOR THE PRODUCTION OF Ad26 ADENOVIRAL VECTORS

Similar Documents

Publication Publication Date Title
JP2012507270A5 (https=)
NZ593235A (en) Method for the production of recombinant adenovirus serotype 35
JP2014521353A5 (https=)
JP2019516410A5 (https=)
CN102762721B (zh) 用于生产Ad26腺病毒载体的方法
CN103732236B (zh) 用于生产痘苗病毒的方法和组合物
Feuchtinger et al. Adenovirus infection after allogeneic stem cell transplantation
JP2011125348A5 (https=)
WO2020076820A3 (en) Compositions and methods for preparing viral vectors
JP2009034115A5 (https=)
JP2004505623A5 (https=)
JP2004501647A5 (https=)
JP2005512564A5 (https=)
JP2006230415A5 (https=)
JP2013515473A5 (https=)
CN104812893A (zh) 高感染滴度的细小病毒的生产方法
Duffy et al. Generation and characterization of a novel candidate gene therapy and vaccination vector based on human species D adenovirus type 56
JP2013538588A5 (https=)
CN107523555A (zh) 获得病毒的方法
JP2008508899A5 (https=)
CN116200348A (zh) 一种适应Vero细胞的柯萨奇病毒A10型毒株的构建方法及其应用
CN114107389A (zh) 表达非洲猪瘟病毒b602l-b646l蛋白的重组腺病毒及构建方法
CN102533657B (zh) 一种人41型腺病毒(Ad41)包装细胞株及其应用
CN103642760B (zh) 一种制备柯萨奇a16型病毒完整实心颗粒的方法
Pelz et al. Production of antiviral “OP7 chimera” defective interfering particles free of infectious virus